Optimizing Respiratory Defense Against Viral Threats
Main Article Content
Abstract
People of all ages are susceptible to respiratory tract viral infections, placing a significant burden on healthcare systems worldwide. Adenoviruses, coronaviruses, rhinoviruses, influenza, and respiratory syncytial virus (RSV) are among the most prevalent respiratory viruses that cause illness, hospitalization, and mortality worldwide. Their fast spread in communal settings is facilitated by their persistence on contaminated surfaces, in droplets, and in aerosols. While certain infections may lead to more serious problems, such as pneumonia or acute respiratory distress syndrome (ARDS), the majority of cases cause only moderate upper respiratory illness. Dryness, temperature fluctuations, and airborne particles are all threats to the respiratory mucosa. Additionally, ventilatory demand increases during exercise, jogging, and daily activities.
Host protection is a multifaceted effort that encompasses physical barriers, mucociliary clearance, adaptive and innate immunity, and optimal lung function. Methods like nose breathing, vaccination, moderate exercise, better air quality, healthy eating, and rehabilitation all contribute to these defenses. Various diagnostic methods, including radiography, molecular and antigen testing, and enhanced genomic monitoring, are utilized throughout the evaluation process.
The therapy options include various methods, such as targeted antivirals, immunomodulatory medications, supportive oxygen therapies, and prophylactic immunizations. Airway hydration, environmental control, and non-pharmaceutical treatments (NPIs) can all work together to increase viral resistance. Lung fibrosis, post-viral fatigue syndrome, persistent airway hyperresponsiveness, and other long-term virus-related consequences necessitate intervention programs. Many problems persist, including the fact that viruses continue to evolve, not everyone has access to vaccines, and communities are still experiencing the effects.
This comprehensive study encompasses a range of topics, including respiratory pathophysiology, the impact of exercise and environment, epidemiologic trends, diagnosis, treatment, and rehabilitation. Supporting airway defenses and helping hosts remain resilient against both new and current viral infections, it stresses evidence-based, real-world techniques.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Killingley B, Nguyen-Van-Tam J. Routes of influenza transmission. Influenza Other Respir Viruses. 2013;7(suppl 2):42-51.
3. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality. Lancet. 2018;391(10127):1285-1300.
4. Shi T, McAllister DA, O’Brien KL, et al. Global burden of RSV in young children. Lancet. 2017;390(10098):946-958.
5. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154.
6. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371-384.
7. Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018;16(1):47-60.
8. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135-162.
9. Bedford T, Riley S, Barr IG, et al. Global circulation patterns of seasonal influenza viruses. Nature. 2015;523(7559):217-220.
10. CIDRAP. US COVID declining after reaching peak. Published 2025. Available from: https://www.cidrap.umn.edu/covid-19/us-covid-declining-after-reaching-peak
11. Centers for Disease Control and Prevention (CDC). 2025–26 Respiratory Season Outlook. Published 2025. Available from: https://www.cdc.gov/cfa-qualitative-assessments/php/data-research/season-outlook25-26.html
12. World Health Organization (WHO). COVID-19 global hospitalization data dashboard. Published 2025. Available from: https://data.who.int/dashboards/covid19/hospitalizations
13. European Centre for Disease Prevention and Control (ECDC). Weekly respiratory virus update, May 2025. Available from: https://www.ecdc.europa.eu/en/publications-data/weekly-respiratory-virus-update-week-19-may-2025
14. World Health Organization (WHO). Disease Outbreak News: Respiratory infections, 2025. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON550
15. Agha R, Avner JR. Delayed RSV epidemic in 2021 after relaxation of COVID-19 measures. Pediatrics. 2021;148(3):e2021052089.
16. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev. 2013;26(1):135-162.
17. Centers for Disease Control and Prevention (CDC). Respiratory virus activity levels. Published 2025. Available from: https://www.cdc.gov/respiratory-viruses/data/activity-levels.html
18. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.
19. Mina MJ, Parker R, Larremore DB. Rethinking COVID-19 test sensitivity. N Engl J Med. 2020;383(22):e120.
20. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7(2):131-137.
21. Altmann DM, Boyton RJ. SARS-CoV-2 T-cell immunity. Nat Rev Immunol. 2020;20(10):587-588.
22. Mehta P, McAuley DF, Brown M, et al. COVID-19: cytokine storm. Lancet. 2020;395(10229):1033-1034.
23. Johnston SL. Viruses and asthma exacerbations. Proc Am Thorac Soc. 2005;2(2):150-156.
24. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045.
25. Scohy A, Anantharajah A, Bodeus M, et al. Low performance of rapid antigen tests for SARS-CoV-2. Int J Infect Dis. 2020;97:244-246.
26. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2. Nat Med. 2020;26(6):845-848.
27. Kanne JP, Little BP, Chung JH, et al. Essentials for radiologists on COVID-19. Radiology. 2020;296(2):E113-E114.
28. Kellner MJ, Koob JG, Gootenberg JS, et al. CRISPR-based diagnostics. Science. 2019;364(6446):1464-1468.
29. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults. Lancet. 2015;385(9979):1729-1737.
30. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for COVID-19. N Engl J Med. 2020;383(19):1813-1826.
31. Griffin MP, Yuan Y, Takas T, et al. Nirsevimab for prevention of RSV. N Engl J Med. 2020;383(5):415-425.
32. Fan E, Beitler JR, Brochard L, et al. Ventilatory support for COVID-19 patients. JAMA. 2020;323(22):2329-2336.
33. RECOVERY Collaborative Group. Dexamethasone in hospitalized COVID-19 patients. N Engl J Med. 2021;384(8):693-704.
34. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2 antibody cocktail in COVID-19. N Engl J Med. 2021;384(3):238-251.
35. Grohskopf LA, Alyanak E, Ferdinands JM, et al. Influenza vaccination recommendations. MMWR Recomm Rep. 2021;70(5):1-24.
36. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
37. Hammitt LL, Dagan R, Yuan Y, et al. RSV vaccine in pregnancy. N Engl J Med. 2022;386(19):1735-1746.
38. Chu DK, Akl EA, Duda S, et al. Physical distancing, masks, and eye protection. Lancet. 2020;395(10242):1973-1987.
39. Hayden FG, Belshe R, Villanueva C, et al. Antiviral prophylaxis in influenza. N Engl J Med. 2004;351(10):997-1007.
40. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.
41. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis after COVID-19. Lancet Respir Med. 2020;8(8):807-815.
42. Gallo O, Locatello LG, Mazzoni A, Novelli L, Annunziato F. The central role of the host immune response in COVID-19. Front Immunol. 2021;12:652383.